# Phase II/III of Recombinant Human Albumin Injection

> **NCT06411743** · PHASE2 · COMPLETED · sponsor: **The First Hospital of Jilin University** · enrollment: 90 (actual)

## Conditions studied

- Hepatic Ascites

## Interventions

- **BIOLOGICAL:** Recombinant Human Albumin Injection
- **BIOLOGICAL:** Human Albumin

## Key facts

- **NCT ID:** NCT06411743
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-07
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-08-15
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411743, "Phase II/III of Recombinant Human Albumin Injection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06411743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*